Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: A case report

Ye Won Chung, Hyo Sook Bae, Song I. Han, Jae Yoon Song, In Sun Kim, Seong Jae Kang

Research output: Contribution to journalArticle

3 Citations (Scopus)


Toremifene is an anti-estrogen which has been shown to be effective in the treatment of breast cancer, and is thought to be a less uterotrophic agent than tamoxifen. The risk assessment concerning endometrial cancer has been inconclusive because of its rare use up to the mid-1990s. We report a case of an adenosarcoma, which is a very rare type of uterine malignancy, after toremifene treatment for 5 years in a breast cancer patient. After 1 year of toremifene use, the patient had a benign Mullerian adenofibroma. After an additional 4 years of toremifene treatment, the endometrial polypoid lesion was transformed into a Mullerian adenosarcoma. Although toremifene is a promising anti-estrogenic agent in the treatment of breast cancer patients, clinicians should not neglect the possibility of a uterine malignancy.

Original languageEnglish
Pages (from-to)269-272
Number of pages4
JournalJournal of gynecologic oncology
Issue number4
Publication statusPublished - 2010 Dec 1



  • Breast cancer
  • Mullerian adenofibroma
  • Mullerian adenosarcoma
  • Tamoxifen
  • Toremifene

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this